x
Filter:
Filters applied
- Clinical Practice Guidelines and Recommendations
- FDARemove FDA filter
Publication Date
Please choose a date range between 2000 and 2019.
Author
- Argoff, Charles E1
- Backonja, Misha-Miroslav1
- Belgrade, Miles J1
- Bennett, Gary J1
- Black, John L1
- Brown, Vivien1
- Christiansen, Kristin1
- Clark, Michael R1
- Cole, B Eliot1
- Elliott, Michelle A1
- Faubion, Stephanie S1
- Fishbain, David A1
- Frye, Mark A1
- Giraldi, Annamaria1
- Goldstein, Sue W1
- Hahn, Steven R1
- Hamilos, Daniel L1
- Hartzell-Cushanick, Rose1
- Henry, Nancy K1
- Hoecker, Jay L1
- Irving, Gordon A1
- Kathrins, Martin1
- Kelly-Jones, Alyse1
- Kingsberg, Sheryl A1
- Larkin, Lisa1
Keyword
- Food and Drug Administration5
- VAS2
- visual analog scale2
- "Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline"1
- ABRS1
- AFRS1
- Aging Males' Symptoms1
- American College of Chest Physicians Antithrombotic Guidelines, 9th edition1
- AMS1
- APS1
- AR1
- ARS1
- AT91
- AUC1
- AVRS1
- Birmingham, Lichfield, Atherstone, Sutton Coldfield, and Tamworth1
- BLAST1
- BMD1
- BMI1
- British Society for Allergy and Clinical Immunology1
- BSACI1
- CEE1
- CHF1
- CI1
Clinical Practice Guidelines and Recommendations
7 Results
- Clinical practice guidelinesOpen Access
The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns and Problems in Women
Mayo Clinic ProceedingsVol. 94Issue 5p842–856Published online: April 3, 2019- Sharon J. Parish
- Steven R. Hahn
- Sue W. Goldstein
- Annamaria Giraldi
- Sheryl A. Kingsberg
- Lisa Larkin
- and others
Cited in Scopus: 32Sexual problems are common in women of all ages. Despite their frequency and impact, female sexual dysfunctions (FSDs) are often unrecognized and untreated in clinical settings. In response, the International Society for the Study of Women's Sexual Health convened a multidisciplinary, international expert panel to develop a process of care (POC) that outlines recommendations for identification of sexual problems in women. This POC describes core and advanced competencies in FSD for clinicians who are not sexual medicine specialists and serve as caregivers of women and, therefore, is useful for clinicians with any level of competence in sexual medicine. - Special article
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine
Mayo Clinic ProceedingsVol. 91Issue 7p897–907Published online: June 17, 2016- Malik Nassan
- Wayne T. Nicholson
- Michelle A. Elliott
- Carolyn R. Rohrer Vitek
- John L. Black
- Mark A. Frye
Cited in Scopus: 53Antidepressants are commonly prescribed medications in the United States, and there is increasing interest in individualizing treatment selection for more than 20 US Food and Drug Administration–approved treatments for major depressive disorder. Providing greater precision to pharmacotherapeutic recommendations for individual patients beyond the large-scale clinical trials evidence base can potentially reduce adverse effect toxicity profiles and increase response rates and overall effectiveness. - Review
Critical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis
Mayo Clinic ProceedingsVol. 90Issue 8p1104–1115Published online: July 20, 2015- Allen D. Seftel
- Martin Kathrins
- Craig Niederberger
Cited in Scopus: 51“Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline” (Guidelines), published in 2010, serves as an important guide for the treatment of hypogonadal men. Using the Guidelines as a basis, we searched for the most recent level 1 evidence that continues to support the recommendations or provide an impetus to modify all or some of them. We performed a systematic analysis with a PubMed query from January 1, 2010, through March 2, 2015, using the following key words: testosterone/deficiency, testosterone/therapeutic use, cardiovascular, morbidity, mortality, screening, sexual function, lower urinary tract symptoms, obstructive sleep apnea, prostate cancer, fertility, bone mineral density, osteoporosis, quality of life, cognitive, erectile dysfunction, and adverse effects. - Review
Succinct Review of the New VTE Prevention and Management Guidelines
Mayo Clinic ProceedingsVol. 89Issue 3p394–408Published in issue: March, 2014- Amy West Pollak
- Robert D. McBane II
Cited in Scopus: 21Venous thromboembolism is a major source of morbidity and mortality in the United States. The American College of Chest Physicians Antithrombotic Guidelines, 9th edition, includes a large number of clinical practice recommendations regarding the diagnosis, treatment, and prevention of venous thromboembolism. This succinct clinical review of these guidelines specifically focuses on the evaluation, treatment, and prevention of venous thromboembolic disease. - REVIEW
Rhinosinusitis Diagnosis and Management for the Clinician: A Synopsis of Recent Consensus Guidelines
Mayo Clinic ProceedingsVol. 86Issue 5p427–443Published in issue: May, 2011- Eli O. Meltzer
- Daniel L. Hamilos
Cited in Scopus: 168Rhinosinusitis (RS) affects approximately 1 in 7 adults in the United States, and its effect on quality of life, productivity, and finances is substantial. During the past 10 years, several expert panels from authoritative bodies have published evidence-based guidelines for the diagnosis and management of RS and its subtypes, including acute viral RS, acute bacterial RS, chronic RS (CRS) without nasal polyposis, CRS with nasal polyposis, and allergic fungal RS. This review examines and compares the recommendations of the Rhinosinusitis Initiative, the Joint Task Force on Practice Parameters, the Clinical Practice Guideline: Adult Sinusitis, the European Position Paper on Rhinosinusitis and Nasal Polyps 2007, and the British Society for Allergy and Clinical Immunology. - SUPPLEMENT ARTICLE
Consensus Guidelines: Treatment Planning and Options
Mayo Clinic ProceedingsVol. 81Issue 4SupplementS12–S25Published in issue: April, 2006- Charles E. Argoff
- Misha-Miroslav Backonja
- Miles J. Belgrade
- Gary J. Bennett
- Michael R. Clark
- B. Eliot Cole
- and others
Cited in Scopus: 155Despite the number of patients affected by diabetic peripheral neuropathic pain (DPNP), little consensus exists about the pathophysiology, best diagnostic tools, and primary treatment choices. Theories about the causes of DPNP are inextricably linked with the causes of diabetic neuropathies, yet most patients with such neuropathies do not experience pain. The factors that differentiate patients with pain from those without remain unknown and are the subject of much research. When choosing treatment for patients with DPNP, physicians are confronted with a myriad of choices, none of which has been shown to be effective for all patients. - Symposium on Antimicrobial Agents—Part XVI
Antimicrobial Therapy for Infants and Children: Guidelines for the Inpatient and Outpatient Practice of Pediatric Infectious Diseases
Mayo Clinic ProceedingsVol. 75Issue 1p86–97Published in issue: January, 2000- Nancy K. Henry
- Jay L. Hoecker
- K. Hable Rhodes
Cited in Scopus: 11In this article, we discuss antimicrobial regimens for both outpatient and inpatient use in infants and children. A substantial number of pediatric patient visits annually result in the prescribing of antimicrobial drugs. The emergence of bacteria resistant to commonly used antimicrobial agents is a growing concern. Information on newer drugs such as meropenem, which is active against penicillin-resistant Streptococcus pneumoniae and gram-negative bacilli, and cefepime, which has activity against gramnegative bacilli including Pseudomonas aeruginosa and against gram-positive cocci is also presented.